Genistein improves thyroid function in Hashimoto's thyroiditis patients through regulating Th1 cytokines

Area of Science:

• Immunology
• Endocrinology
• Nutritional Science

Background:

• Hashimoto thyroiditis (HT) is a prevalent autoimmune condition affecting the thyroid gland.
• Genistein, an isoflavone, exhibits known immunomodulatory properties relevant to autoimmune diseases.

Purpose of the Study:

• To evaluate the efficacy and safety of genistein in patients diagnosed with Hashimoto thyroiditis.
• To investigate the impact of genistein on thyroid hormone levels, thyroid autoantibodies, and immune cell function in HT patients.

Main Methods:

• A double-blind, randomized, placebo-controlled clinical trial involving 218 participants with HT.
• Assessment of serum levels of thyroxine (T4), free thyroxine (fT4), thyroid-stimulating hormone (TSH), thyroperoxidase antibodies (TPOAb), and thyroglobulin antibodies (TgAb).
• Analysis of Th1-related cytokines, including interferon-gamma (IFN-γ) and interleukin-2 (IL-2), to understand immune modulation mechanisms.

Main Results:

• Genistein treatment led to significant increases in T4 and fT4 levels compared to placebo.
• Patients receiving genistein showed significant reductions in TSH, TPOAb, and TgAb levels.
• Observed changes in IFN-γ and IL-2 suggest genistein modulates HT through regulating Th1 cell function.

Conclusions:

• Genistein administration is effective and well-tolerated in managing Hashimoto thyroiditis.
• Genistein demonstrates a clear immunological effect in HT patients, warranting further investigation.
• Future research should explore long-term effects and potential chemopreventive roles against thyroid cancer in HT.